{"product_id":"mbio-vrio-analysis","title":"Mustang Bio, Inc. (MBIO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage for Mustang Bio, Inc. (MBIO) hinges on a rigorous examination of its core assets. Our VRIO Analysis, detailed below in section '\u0026amp;O4\u0026amp;', distills whether its current resources are truly Valuable, Rare, Inimitable, and Organized to generate superior returns. Discover immediately if Mustang Bio, Inc. (MBIO) possesses the foundational elements for long-term market dominance or if strategic shifts are urgently required.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 1. Orphan Drug Designation for MB-101\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the immediate impact of the July 7, 2025, Orphan Drug Designation (ODD) from the FDA for Mustang Bio's MB-101, and frankly, it's a significant near-term catalyst that changes the risk\/reward profile for this asset.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Market Incentives and Early Efficacy\u003c\/h3\u003e\n\u003cp\u003eThe ODD itself is a direct injection of value, providing Mustang Bio with tax credits for clinical trial costs upon approval and waivers for prescription drug user fees. More importantly, it locks in \u003cstrong\u003eseven years\u003c\/strong\u003e of market exclusivity for the designated indication if the therapy gets the green light. This is crucial for a company valued at \u003cstrong\u003e$55.6 million\u003c\/strong\u003e as of the announcement date. We also have early clinical proof; in the ongoing Phase 1 trial, \u003cstrong\u003e50%\u003c\/strong\u003e of patients achieved stable disease or better, with two patients showing durable complete responses lasting \u003cstrong\u003e7.5\u003c\/strong\u003e and \u003cstrong\u003e66+ months\u003c\/strong\u003e. That’s the kind of signal investors look for in these hard-to-treat cancers.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Specific Regulatory Win\u003c\/h3\u003e\n\u003cp\u003eGetting an ODD for a specific CAR-T therapy targeting recurrent diffuse and anaplastic astrocytoma and glioblastoma is genuinely rare in the current oncology landscape. It signals the FDA sees a real unmet need that existing treatments aren't meeting effectively. This designation, coupled with the prior ODD for MB-108, validates the science behind the planned MB-109 combination.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Regulatory Barrier to Entry\u003c\/h3\u003e\n\u003cp\u003eThis is not a patent that a competitor can design around easily; it’s a regulatory grant based on preclinical and early clinical data showing potential benefit in a rare disease population. Competitors would need to replicate the entire development and submission process to gain the same status, which takes time and capital. It’s a high, albeit temporary, barrier.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Execution Post-Designation\u003c\/h3\u003e\n\u003cp\u003eMustang Bio is clearly organized to exploit this win. Management, led by CEO Manuel Litchman, immediately highlighted the designation in their press release, showing it’s central to their investor messaging. The next action is clear: securing funding or a strategic partnership to advance the combination therapy, MB-109, into the planned Phase 1 study in Q1 2026. The company’s H1 2025 net loss of USD \u003cstrong\u003e0.92 million\u003c\/strong\u003e shows they are managing burn, but the next funding round is defintely the priority.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the context around this key asset as of the designation:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue\/Status (as of July 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMB-101 ODD Grant Date\u003c\/td\u003e\n    \u003ctd\u003eJuly 7, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMarket Exclusivity Term\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e7\u003c\/strong\u003e Years (upon approval)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePhase 1 Efficacy (SD or better)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompany Market Cap\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$55.6 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStock Price (Approx.)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$1.88\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Not Sustained Yet\u003c\/h3\u003e\n\u003cp\u003eRight now, you have a \u003cstrong\u003etemporary competitive advantage\u003c\/strong\u003e. The ODD is a powerful lever, but the true sustained advantage hinges entirely on successful Phase 3 data and ultimate commercialization. If MB-109 proves superior in a larger trial, the exclusivity window combined with the novelty of the CAR-T\/oncolytic virus approach could translate this into a sustained advantage. Until then, it’s a high-potential, near-term benefit.\u003c\/p\u003e\n\u003cp\u003eFinance: Draft the funding requirement analysis for the MB-109 Phase 1 initiation by end of next week.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 2. Chimeric Antigen Receptor T-cell (CAR-T) Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Forms the scientific foundation for their oncology pipeline, allowing for the development of targeted cell therapies against various cancers.\u003c\/p\u003e\n\u003cp\u003eThe platform's value is demonstrated through clinical efficacy in both hematologic and solid tumor indications:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMB-106 (CD20-targeted CAR T):\u003c\/strong\u003e Achieved an overall response rate (ORR) of \u003cstrong\u003e100%\u003c\/strong\u003e in patients with Follicular Lymphoma (FL) and Waldenstrom Macroglobulinemia (WM) in a multicenter Phase 1\/2 trial (as of December 2023 data). In an earlier trial, the ORR was \u003cstrong\u003e96%\u003c\/strong\u003e with a complete response (CR) rate of \u003cstrong\u003e75%\u003c\/strong\u003e. Durability includes CAR T-cell persistence up to \u003cstrong\u003e3 years\u003c\/strong\u003e in the original single institution trial.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMB-101 (IL13R$\\alpha$2-targeted CAR T for High-Grade Glioma):\u003c\/strong\u003e In a Phase 1 trial, \u003cstrong\u003e50%\u003c\/strong\u003e ($\\mathbf{29\/58}$) of heavily pretreated patients achieved stable disease or better for at least \u003cstrong\u003etwo months\u003c\/strong\u003e. Two patients with 'hot' tumors achieved complete responses lasting \u003cstrong\u003e7.5\u003c\/strong\u003e and \u003cstrong\u003e66+ months\u003c\/strong\u003e. The median overall survival for all patients was \u003cstrong\u003eeight months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e CAR-T technology itself is not rare, but proprietary vector designs or specific target\/construct combinations can be.\u003c\/p\u003e\n\u003cp\u003eRarity is supported by specific indications and trial designs:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMB-106 targets WM, a subtype of indolent lymphoma with \u003cstrong\u003eno FDA-approved CAR-T\u003c\/strong\u003e therapy.\u003c\/li\u003e\n\u003cli\u003eMB-101 targets IL13R$\\alpha$2 in high-grade glioma and represents one of the largest reported trials to date of CAR-T therapy for solid tumors, with \u003cstrong\u003e58\u003c\/strong\u003e patients evaluable for disease response.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately imitable; core science is known, but specific, optimized constructs and manufacturing know-how are harder to copy.\u003c\/p\u003e\n\u003cp\u003eImitability challenges are suggested by manufacturing and delivery optimization:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eData\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOptimized Delivery (MB-101)\u003c\/td\u003e\n\u003ctd\u003eFinal cohort with dual intratumoral (ICT)\/intraventricular (ICV) delivery showed median overall survival of \u003cstrong\u003e10.2 months\u003c\/strong\u003e vs. expected \u003cstrong\u003esix months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Status (MB-106)\u003c\/td\u003e\n\u003ctd\u003eMustang had manufactured product for \u003cstrong\u003eall enrolled patients\u003c\/strong\u003e in its multicenter trial as of year-end 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment (2023)\u003c\/td\u003e\n\u003ctd\u003eResearch and development expenses were \u003cstrong\u003e$40.5 million\u003c\/strong\u003e for the year ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is structured to translate these breakthroughs, evidenced by their lead candidate, MB-101.\u003c\/p\u003e\n\u003cp\u003eOrganizational focus is evidenced by clinical progression and regulatory milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMustang plans to request Regenerative Medicine Advanced Therapy (RMAT) designation for indolent lymphoma in the \u003cstrong\u003efirst half of 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company anticipates treating the first patient in a pivotal Phase 2 trial for WM in the \u003cstrong\u003esecond half of 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMB-101 received Orphan Drug Designation from the FDA for astrocytomas and glioblastoma.\u003c\/li\u003e\n\u003cli\u003eAs of December 31, 2023, the company reported \u003cstrong\u003e6\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the field evolves rapidly, requiring continuous platform improvement.\u003c\/p\u003e\n\u003cp\u003eThe temporary nature is underscored by the need for combination strategies and current financial position:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMB-101 development is being advanced via a novel combination with MB-108 (HSV-1 oncolytic virus) to reshape the tumor microenvironment.\u003c\/li\u003e\n\u003cli\u003eAs of December 31, 2023, cash and cash equivalents totaled \u003cstrong\u003e$7.0 million\u003c\/strong\u003e, down from \u003cstrong\u003e$76.7 million\u003c\/strong\u003e as of December 31, 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 3. Strategic Academic Collaboration Network\n\u003c\/h2\u003e\n\u003cp\u003eThe strategic academic collaboration network provides the foundation for clinical development across Mustang Bio's pipeline.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAccess to cutting-edge research and clinical trial sites is provided through partnerships essential for a clinical-stage biotech company.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOngoing clinical trials involving therapeutic candidates include six trials as of a prior report, such as those for MB-101 (NCT04661384, NCT02208362, NCT04003649), MB-106 (NCT03277729), and MB-108 (NCT03657576).\u003c\/li\u003e\n\u003cli\u003eThe development of MB-106 is in collaboration with Fred Hutchinson Cancer Center (“Fred Hutch”).\u003c\/li\u003e\n\u003cli\u003eThe development of the in vivo CAR T platform technology is in collaboration with Mayo Clinic.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003ePartnerships with 'top medical institutions' are common, but the quality and exclusivity of the specific agreements matter.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCollaborating Institution\u003c\/th\u003e\n\u003cth\u003eProgram Focus\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFred Hutch Cancer Center\u003c\/td\u003e\n\u003ctd\u003eMB-106 (CD20 CAR T-cell therapy)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e Overall Response Rate in WM cohort\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCity of Hope\u003c\/td\u003e\n\u003ctd\u003eMB-101 (CAR T-cell therapy)\u003c\/td\u003e\n\u003ctd\u003ePhase 1 clinical trials enrolling patients with recurrent GBM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMayo Clinic\u003c\/td\u003e\n\u003ctd\u003eIn vivo CAR T platform technology\u003c\/td\u003e\n\u003ctd\u003eActive development collaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNationwide Children's Hospital\u003c\/td\u003e\n\u003ctd\u003eMB-109 (Combination therapy)\u003c\/td\u003e\n\u003ctd\u003eActive collaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eRelationships take time to build, but competitors can pursue similar institutions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCollaboration with City of Hope for developing and optimizing cell processing procedures has been ongoing since January 2018.\u003c\/li\u003e\n\u003cli\u003eThe strategic manufacturing partnership with uBriGene (Boston) Biosciences Inc. involves a total consideration of up to \u003cstrong\u003e$11 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company relies on these partnerships to advance development, showing an organizational structure that supports external science translation.\u003c\/p\u003e\n\u003cp\u003eThe IND filing for MB-109, a combination therapy leveraging MB-101 and MB-108, was planned for filing in 2023.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary, as relationships can shift based on performance and new opportunities.\u003c\/p\u003e\n\u003cp\u003eMB-106 in Waldenstrom Macroglobulinemia demonstrated \u003cstrong\u003e3\u003c\/strong\u003e complete responses out of 10 patients treated, with one patient in complete remission at 31 months.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 4. Outsourced GMP Manufacturing Agreement with uBriGene\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below pertains to the strategic manufacturing partnership and asset sale with uBriGene (Boston) Biosciences Inc., which closed in July 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Expected significant reduction in annualized operating and interest expense by at least \u003cstrong\u003e$28 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A strategic divestiture and partnership with a CDMO (Contract Development and Manufacturing Organization) is a common, but well-executed, cost-saving move.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately imitable; the specific terms and quality of the partnership are unique to Mustang Bio.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The July 2023 asset sale and partnership show a clear organizational decision to optimize resource allocation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as manufacturing costs and CDMO availability can change over time.\u003c\/p\u003e\n\u003cp\u003eFinancial and Statistical Data Related to Manufacturing Restructuring:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003ctd\u003eSource\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Annualized Expense Reduction\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e$28 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFrom uBriGene transaction (Expected)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003euBriGene Asset Sale Upfront Consideration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6 million\u003c\/strong\u003e in cash\u003c\/td\u003e\n\u003ctd\u003eClosing on July 28, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Payment from uBriGene\u003c\/td\u003e\n\u003ctd\u003eAdditional \u003cstrong\u003e$5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePayable upon Mustang raising \u003cstrong\u003e$10 million\u003c\/strong\u003e in gross equity proceeds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential uBriGene Consideration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$11 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAsset purchase agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFixed Assets Sale Price to AbbVie\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025 asset divestment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Lease Expense Savings\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOver the next \u003cstrong\u003e24 months\u003c\/strong\u003e from lease termination (February 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational and Operational Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe transaction with uBriGene included the sale of Mustang Bio's development, manufacturing and analytical testing facility in Worcester, Massachusetts.\u003c\/li\u003e\n\u003cli\u003euBriGene is a cell and gene therapy Contract Development and Manufacturing Organization (CDMO).\u003c\/li\u003e\n\u003cli\u003eMustang Bio relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts, in February 2025.\u003c\/li\u003e\n\u003cli\u003eMustang Bio anticipates supporting and initiating a novel clinical trial with MB-109 in the second half of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 5. Clinical Development and Regulatory Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows the company to navigate complex FDA processes, such as securing the July 2025 Orphan Drug Designation and managing trials.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eRegulatory Status\/Milestone\u003c\/th\u003e\n\u003cth\u003eKey Efficacy Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-101\u003c\/td\u003e\n\u003ctd\u003eAstrocytomas and Glioblastoma (GBM)\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD) granted on \u003cstrong\u003eJuly 7, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e of patients achieved stable disease or better in Phase 1 trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-108\u003c\/td\u003e\n\u003ctd\u003eMalignant Glioma\u003c\/td\u003e\n\u003ctd\u003eODD previously granted\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-106\u003c\/td\u003e\n\u003ctd\u003eWaldenstrom Macroglobulinemia (WM)\u003c\/td\u003e\n\u003ctd\u003eNo FDA-approved CAR-T treatments currently for WM\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e Overall Response Rate in cohort of \u003cstrong\u003e10\u003c\/strong\u003e heavily pretreated\/refractory patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Expertise in cell therapy development and regulatory affairs is a necessary, but not unique, asset in this sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately imitable; key personnel can be hired away, but deep institutional knowledge is sticky.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The management team is noted for having expertise in these specific areas, suggesting effective internal structure.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePresident and Chief Executive Officer, Manuel Litchman, M.D., led the CTL019 (CD19 CAR T) collaboration at Novartis.\u003c\/li\u003e\n\u003cli\u003eChief Scientific Officer, Sadik Kassim, Ph.D., played a key role in the Biologics License Application filing for Kymriah™ at Novartis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eResearch and development expenses were \u003cstrong\u003e$40.5 million\u003c\/strong\u003e for the year ended \u003cstrong\u003eDecember 31, 2023\u003c\/strong\u003e, compared to \u003cstrong\u003e$62.5 million\u003c\/strong\u003e for \u003cstrong\u003e2022\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eAs of \u003cstrong\u003eDecember 31, 2023\u003c\/strong\u003e, cash and cash equivalents totaled \u003cstrong\u003e$7.0 million\u003c\/strong\u003e, a decrease from \u003cstrong\u003e$76.7 million\u003c\/strong\u003e as of \u003cstrong\u003eDecember 31, 2022\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company's market capitalization was reported at \u003cstrong\u003e$55.6 million\u003c\/strong\u003e as of July 7, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, dependent on retaining key personnel with specific experience.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTwo complete responses for MB-101 were observed in the cohort of \u003cstrong\u003e3\u003c\/strong\u003e patients with the 'hottest' tumors prior to treatment.\u003c\/li\u003e\n\u003cli\u003eOne patient treated with MB-106 has remained in complete remission for \u003cstrong\u003e31 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eYear to date (as of July 2025), MBIO shares had plunged \u003cstrong\u003e62.3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 6. Current Nasdaq Listing Status (MBIO)\n\u003c\/h2\u003e\n\u003cp\u003eThe continued listing on The Nasdaq Stock Market provides MBIO with access to public capital markets necessary for institutional engagement and future financing activities.\u003c\/p\u003e\n\n\u003cp\u003eThe company recently executed a significant corporate action to maintain this status.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCompliance Metric\/Action\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eDate\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReverse Stock Split Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1-for-50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEffective January 16, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Split Outstanding Shares (Approx.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e64.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to January 16, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Split Outstanding Shares (Approx.)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAfter January 16, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Bid Price Requirement (Rule 5550(a)(2))\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.00\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003eRequirement for continued listing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Stockholders' Equity Requirement (Rule 5550(b)(1))\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMinimum required equity level\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDate Equity Compliance Regained\u003c\/td\u003e\n\u003ctd\u003eFormal Notice Received\u003c\/td\u003e\n\u003ctd\u003eFebruary 26, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maintains access to public capital markets and provides a level of credibility required for institutional partnerships and future financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Being listed on Nasdaq is common, but maintaining compliance after a \u003cstrong\u003e1-for-50\u003c\/strong\u003e reverse stock split in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e is a recent achievement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Not imitable; it is a status granted by the exchange, though competitors face similar hurdles.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company successfully executed a \u003cstrong\u003e1-for-50\u003c\/strong\u003e reverse stock split to meet the minimum bid price requirement, showing organizational agility.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe reverse split was approved by stockholders representing approximately \u003cstrong\u003e56%\u003c\/strong\u003e of the voting power on \u003cstrong\u003eJune 27, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company regained compliance with the minimum stockholders' equity requirement of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e on \u003cstrong\u003eFebruary 26, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRecent balance sheet data indicates total shareholder equity of \u003cstrong\u003e$9.8M\u003c\/strong\u003e, total assets of \u003cstrong\u003e$19.4M\u003c\/strong\u003e, and total liabilities of \u003cstrong\u003e$9.6M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as they must continuously meet listing rules, like the \u003cstrong\u003e$2.5 million\u003c\/strong\u003e stockholders' equity requirement.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 7. Recent Equity Financing Buffer\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The February 2025 public offering provided approximately \u003cstrong\u003e$8 million\u003c\/strong\u003e in gross proceeds, bolstering liquidity.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Capital raises are routine, but the timing relative to operational needs is key; this provided a needed cash buffer. The offering was priced at a combined \u003cstrong\u003e$3.01\u003c\/strong\u003e per share for \u003cstrong\u003e2,657,807\u003c\/strong\u003e shares and accompanying warrants.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Not imitable; this is a historical transaction, though the ability to raise capital is a capability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company demonstrated the ability to access public markets to fund working capital and general corporate purposes. Following the closing, the Company believed it met the minimum stockholders' equity requirement for continued Nasdaq listing, estimated at a minimum of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this cash buffer will be depleted by ongoing R\u0026amp;D and operational burn. For the quarter ended September 30, 2025, Net cash used in operating activities was \u003cstrong\u003e$(3,546)\u003c\/strong\u003e thousand.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds (Feb 2025 Offering)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares\/Equivalents Sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,657,807\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined Offering Price per Unit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.01\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrants Issued (Total Potential Shares)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e5,315,614\u003c\/strong\u003e (Series C-1 and C-2 combined)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq Equity Requirement (Believed Met)\u003c\/td\u003e\n\u003ctd\u003eMinimum of \u003cstrong\u003e$2.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(3,546) thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financing structure included specific instruments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSeries C-1 Warrants: 5-year expiration, exercisable upon stockholder approval.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSeries C-2 Warrants: 24-month expiration, exercisable upon stockholder approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 8. Lentiviral Gene Therapy Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies the company beyond oncology into rare genetic diseases, offering a second potential revenue stream and de-risking the pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having both CAR-T and gene therapy platforms is a broader, though not entirely unique, strategic position.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately imitable; requires distinct IP and manufacturing expertise for the lentiviral vectors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The structure supports advancing both cell and gene therapy candidates simultaneously.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the success of these distinct programs is still in the clinical stage.\u003c\/p\u003e\n\n\u003cp\u003eThe lentiviral gene therapy portfolio is primarily focused on X-linked severe combined immunodeficiency (XSCID), with candidates MB-107 and MB-207 targeting different patient populations, alongside an exclusive license for RAG1-SCID therapy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCandidate\u003c\/th\u003e\n\u003cth\u003eTarget Indication\u003c\/th\u003e\n\u003cth\u003eClinical Trial Status\/Data Point\u003c\/th\u003e\n\u003cth\u003eAssociated Metric\/Number\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-107\u003c\/td\u003e\n\u003ctd\u003eXSCID (Newly Diagnosed Infants)\u003c\/td\u003e\n\u003ctd\u003eInterim Phase 1\/2 Data Cohort Size (ASGCT 2022)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e23\u003c\/strong\u003e infants treated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-107\u003c\/td\u003e\n\u003ctd\u003eXSCID (Newly Diagnosed Infants)\u003c\/td\u003e\n\u003ctd\u003eMedian Follow-up (ASGCT 2022 Data)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.4 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-107\u003c\/td\u003e\n\u003ctd\u003eXSCID (Newly Diagnosed Infants)\u003c\/td\u003e\n\u003ctd\u003eImmune Reconstitution (Follow-up \u0026gt;6 months)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17 of 18\u003c\/strong\u003e patients achieved robust reconstitution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMB-207\u003c\/td\u003e\n\u003ctd\u003eXSCID (Previously Treated\/Re-treated)\u003c\/td\u003e\n\u003ctd\u003ePlanned Enrollment for Phase 2 Trial\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAG1-SCID Therapy\u003c\/td\u003e\n\u003ctd\u003eRAG1-SCID\u003c\/td\u003e\n\u003ctd\u003eLicense Agreement Date\u003c\/td\u003e\n\u003ctd\u003eNovember 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific data points from the MB-107 clinical trial in newly diagnosed infants under the age of two include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedian age at treatment: \u003cstrong\u003e3 months\u003c\/strong\u003e (range: 2.4-13.8).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedian vector copy number (VCN) per cell: \u003cstrong\u003e0.81\u003c\/strong\u003e (range: 0.16-1.81).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedian CD34+ cell dose: \u003cstrong\u003e9.61x10\u003csup\u003e6\u003c\/sup\u003e\/kg\u003c\/strong\u003e (range 4.4-18.95).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAll treated patients with follow-up greater than 4 months recovered from pre-existing infections and have normal growth velocity: \u003cstrong\u003e20 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company also received a grant from the National Cancer Institute of approximately \u003cstrong\u003e$2 million\u003c\/strong\u003e to partially fund the MB-106 CAR T cell trial, which supports the overall R\u0026amp;D structure that manages both cell and gene therapy programs.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eMustang Bio, Inc. (MBIO) - VRIO Analysis: 9. Originating Sponsor Relationship (Fortress Biotech)\n\u003c\/h2\u003e\n\u003cp\u003eMustang Bio, Inc. was founded in 2015 by Fortress Biotech, Inc. (Nasdaq: FBIO).\u003c\/p\u003e\n\u003cp\u003eThe relationship structure involves Fortress's chairman and CEO also serving on Mustang's board.\u003c\/p\u003e\n\u003cp\u003eFortress Biotech's beneficial ownership in MBIO has been reported to have dropped to 7.9%.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides a historical link to an established entity, which can imply initial seed funding, strategic oversight, or shared resources.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eBeing founded by Fortress Biotech, Inc. (Nasdaq: FBIO) is a specific historical fact.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eNot imitable; this is a fixed historical relationship.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eWhile the relationship is historical, it informs the company's foundational structure and initial resource base. The cumulative net loss for the nine months ended September 30, 2025, was \\$1.38 million.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eSustained, as a historical relationship often implies a degree of ongoing, albeit perhaps passive, support or shared DNA.\u003c\/p\u003e\n\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow Projection Incorporating Q3 2025 Burn Rate and Specified Cash Change\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Q3 2025 Free Cash Flow burn rate is utilized as the basis for the weekly operating cash burn projection: $\\frac{\\$818,000 \\text{ (Q3 25 FCF Burn)}}{13 \\text{ weeks}} \\approx \\mathbf{\\$62,923}$ per week.\u003c\/p\u003e\n\u003cp\u003eThe latest reported Total Cash as of the most recent filing date was \\$18.98M.\u003c\/p\u003e\n\u003cp\u003eThe projection incorporates an assumed \\$7.39M cash inflow from financing activities in Week 1.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003eWeeks 2-13 (12 Weeks)\u003c\/td\u003e\n\u003ctd\u003eTotal 13 Weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$18,980,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated Ending Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$18,980,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Operating Activities (Burn)\u003c\/td\u003e\n\u003ctd\u003e-\\$62,923\u003c\/td\u003e\n\u003ctd\u003e-\\$755,076 (12  \\$62,923)\u003c\/td\u003e\n\u003ctd\u003e-\\$818,000 (Approx. Q3 Burn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Financing Activities (Specified)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+\\$7,390,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\\$0\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+\\$7,390,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Change in Cash\u003c\/td\u003e\n\u003ctd\u003e+\\$7,327,077\u003c\/td\u003e\n\u003ctd\u003e-\\$755,076\u003c\/td\u003e\n\u003ctd\u003e+\\$6,572,001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$26,307,077\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated Ending Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$25,552,001\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Q3 2025 Net Loss was reported as \\$0.468 million.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMBIO is a clinical-stage biopharmaceutical company.\u003c\/li\u003e\n\u003cli\u003eThe company's common stock is registered under the Securities Exchange Act of 1934, as amended.\u003c\/li\u003e\n\u003cli\u003eMBIO files periodic reports with the U.S. Securities and Exchange Commission (SEC).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516204703893,"sku":"mbio-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/mbio-vrio-analysis.png?v=1740197104","url":"https:\/\/dcf-model.com\/pt\/products\/mbio-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}